IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 19 Aug 2016
At a glance
- Drugs Bortezomib (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IFM 2014-02
- 18 Aug 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Sep 2019 to 1 Jan 2020.
- 18 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 31 Jul 2014 New trial record